We are SANOBIOTEC

A team dedicated to the development, production, marketing and validation of minor cannabinoids.

ABOUT US

At Sanobiotec, we are committed to cannabinoid research and development for a broad range of applications in the pharmaceutical and wellness industries. Our portfolio includes both mainstream and rare cannabinoids, including the sought-after THCV, CBN, CBC and CBDV, and a significant IP collection which also covers patentable processes. The combination of synthesis, biosynthesis and extraction capabilities enables the development of optimal production methods for each compound, leading to superior quality and efficiency.

OUR WORK

We are fascinated with cannabinoids, their untapped potential and possibilities. Minor cannabinoids are particularly appealing in this regard and they are finally gaining the well-deserved attention. Research of these compounds is rapidly accelerating, and so does the interest in clinical applications of cannabinoid pharmaceuticals. Our partnerships with leading scientific organisations help us to concentrate deeper on this group of products and expand our R&D capabilities.

OUR VALUES

Our people are living and breathing cannabinoid innovation and share a mission to reveal the true health power of cannabinoids. Our values help us define our purpose as ENABLERS: Excellence oriented, Nature driven, Ambitious, Balanced, Learning, Empowering, Responsible and Sustainable.

Click here to see our video

OUR COMPANIES

Sanobiotec is a group of four companies, all having their unique approach towards cannabinoids.

Sanobiotec Hub sets our strategic business directions, maintains and establishes partnerships and nurtures the people behind the brands.

Sanobiotec R&D develops new products and testing methods, transfers products to further production stages, provides know-how and support.

Sanobiotec Bio conducts product validation research and explores the processes of complex biosynthetic pathways.

Sanobiotec Novus takes care of the manufacturing, sales and customer services.

Sanobiotec Refines Production of CBC: Non-psychoactive Cannabinoid with Unique Therapeutic Potential

Non-psychoactive components of Cannabis Sativa continue to make inroads in medicine with numerous studies demonstrating their comprehensive therapeutic potential.... read more →

16/03/2021

EIHA Consortium Submits Novel Foods Application to FSA

EIHA projects GmbH, together with ChemSafe, their scientific provider, announced that they have submitted Novel Foods applications for natural CBD isolate and Full Spectrum; fully meeting the Food Safety Authority (FSA) deadline.... read more →

01/03/2021

Natural vs Synthetic: Do ‘green’ cannabinoids always come out on top?

Synthetic cannabinoids are often regarded as a lower-quality alternative, but often they surpass natural compounds in terms of product quality and purity, Professor Edvinas Orentas, head of research at Sanobiotec, argues here. ... read more →

04/02/2021

The Budding Field of Cannabis Pharmaceuticals

Positive regulatory developments are aiding the growth of the cannabis pharmaceuticals market, but more clinical data are needed to break the stigma and bring science to the fore.... read more →

02/02/2021

Extracting cannabinoids at scale: how chromatography is paving the way for pure compounds

Therapeutic use of cannabis is a growing industry increasingly accepted by the medical community and general public — but that growth may be stopped if biopharma companies lack reliable methods to extract and purify potentially useful compounds from the plant. ... read more →

16/12/2020

Minor cannabinoid could “revolutionise” autism medication

Out of more than a hundred cannabinoids that have so far been identified in the cannabis sativa plant, the non-intoxicating cannabidivarin (CBDV)... read more →

07/11/2020

About us